In an effort to target this dysfunctional mechanism common to many cancer types, Karyopharm Therapeutics has developed Selective Inhibitor of Nuclear Export (SINE) compounds which bind to and inhibit XPO1 function [24]. This evidence concerns the gene XPO1 and cancer.